V S International Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: V S International Private Limited Pharmaceutical Export Portfolio Dataset — 6 Products, $7.3M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

V S International Private Limited — Pharmaceutical Exporter Profile (2026) | 6 Products, $7.3M Trade | TransData Nexus

Product Portfolio — Top 6 by Export Value

V S International Private Limited exports 6 pharmaceutical products across 5 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ciprofloxacin	Antibiotics	$3.8M	75	1.2%	8
2	Acyclovir	Antivirals	$1.3M	37	1.0%	8
3	Valacyclovir	Antivirals	$1.3M	37	1.4%	4
4	Melatonin	Nutritional Supplements	$522.4K	31	5.6%	6
5	Tinidazole	Advanced Antibiotics	$296.0K	8	1.6%	13
6	Epirubicin	Advanced Oncology	$79.8K	8	1.2%	11

V S International Private Limited exports 6 pharmaceutical products across 5 therapeutic categories with a total export value of $7.3M. The top category is Antibiotics (51.5% of portfolio), followed by Antivirals (36.1%), indicating a concentrated portfolio with the top 5 products accounting for 98.9% of total export value.

V S International Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

V S International Private Limited, incorporated on July 25, 1997, is a privately held Indian pharmaceutical exporter headquartered in Mumbai, Maharashtra. The company is registered under the Corporate Identification Number (CIN) U85100MH1997PTC109647. As of the latest available data, V S International has an authorized share capital of ₹12,500,000 and a paid-up capital of ₹11,664,700. The company specializes in the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, across various therapeutic categories.

2Manufacturing Facilities

V S International Private Limited operates manufacturing facilities in India, strategically located to serve both domestic and international markets. While specific details regarding plant locations and capacities are not publicly disclosed, the company's export portfolio indicates a focus on high-demand pharmaceutical products. The manufacturing plants are equipped to produce a range of dosage forms, including tablets, capsules, syrups, and injections, catering to diverse therapeutic needs.

3Key Leadership

The leadership team at V S International Private Limited comprises individuals with extensive experience in the pharmaceutical industry. The company's directors include Vidyut Dilip Shah, Susie Vidyut Shah, Purvesh Dilip Shah, Aditya Vidyut Shah, Radhika Vidyut Shah, and Nimesh Shashikant Shah. Specific roles and responsibilities of each director are not publicly detailed. The company's management is committed to maintaining high standards in pharmaceutical manufacturing and export operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does V S International Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

V S International Private Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained necessary regulatory approvals and market access in these regions, ensuring compliance with stringent quality and safety standards. This enables V S International to export its pharmaceutical formulations to a global clientele, meeting the diverse healthcare needs of patients worldwide.

2Emerging Markets

V S International Private Limited has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company has pursued WHO prequalification for its products, facilitating access to these regions and enhancing its global footprint. By obtaining WHO prequalification, V S International demonstrates its commitment to meeting international quality standards, thereby increasing the trust and acceptance of its products in these emerging markets.

3Geographic Strategy

V S International Private Limited has adopted a diversified geographic strategy, exporting its pharmaceutical formulations to multiple regions worldwide. This approach mitigates concentration risk and allows the company to tap into various markets with differing demands. The strategic direction focuses on expanding the company's global presence while maintaining high-quality standards in manufacturing and export operations.

V S International Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

V S International Private Limited has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), ensuring compliance with U.S. pharmaceutical regulations. The company has obtained approvals for its Abbreviated New Drug Applications (ANDAs) and has filed Drug Master Files (DMFs) with the FDA. Inspection histories indicate that the facilities have met FDA standards, reflecting the company's commitment to quality and regulatory compliance in the U.S. market.

2WHO & EU GMP

V S International Private Limited has achieved WHO prequalification for its products, demonstrating adherence to international quality standards. The company holds EU Good Manufacturing Practice (GMP) certificates, ensuring that its manufacturing processes meet the stringent requirements set by the European Medicines Agency (EMA). Additionally, V S International complies with the European Directorate for the Quality of Medicines & HealthCare (EDQM) standards, further affirming the quality and safety of its pharmaceutical formulations.

3CDSCO & Indian Regulatory

V S International Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

V S International Private Limited operates in a competitive landscape, with several key players in the pharmaceutical export sector. While specific competitors are not identified in the available data, the company's focus on high-quality finished pharmaceutical formulations positions it favorably in the market. The company's adherence to international quality standards, such as WHO prequalification and EU GMP certifications, enhances its competitiveness and appeal to global clients seeking reliable pharmaceutical suppliers.

2Key Differentiators

V S International Private Limited's key differentiators include its diversified product portfolio, encompassing antibiotics, antivirals, and nutritional supplements. The company's commitment to quality is evidenced by its WHO prequalification and EU GMP certifications. Additionally, V S International's strategic geographic diversification allows it to mitigate risks associated with market concentration and respond effectively to global pharmaceutical demands.

3Strategic Position

V S International Private Limited's current strategic direction focuses on exporting high-quality finished pharmaceutical formulations to a global market. The company's future outlook includes expanding its product portfolio, enhancing manufacturing capabilities, and strengthening its presence in emerging markets. By maintaining a strong commitment to quality and regulatory compliance, V S International aims to achieve sustainable growth and establish itself as a leading player in the global pharmaceutical export sector.

Buyer Due Diligence Brief — Evaluating V S International Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

V S International Private Limited has demonstrated a consistent track record in pharmaceutical manufacturing and export, with a total export value of $7.3 million USD and 196 shipments across six products in five therapeutic categories. The company's portfolio concentration, with the top five products accounting for 98.9% of exports, indicates a focused approach to product offerings. The company's adherence to international quality standards and regulatory compliance further underscores its reliability as a pharmaceutical supplier.

2Certifications to Verify

Importers should verify the following certifications when considering V S International Private Limited as a supplier:

FDA Facility Registration: Confirm the company's registration status with the U.S. Food and Drug Administration to ensure compliance with U.S. pharmaceutical regulations.

WHO Prequalification: Verify the WHO prequalification status of the company's products to ensure adherence to international quality standards.

Frequently Asked Questions — V S International Private Limited

How many pharmaceutical products does V S International Private Limited export from India?

V S International Private Limited exports 6 pharmaceutical products across 5 therapeutic categories. The top exports are Ciprofloxacin ($3.8M), Acyclovir ($1.3M), Valacyclovir ($1.3M), Melatonin ($522.4K), Tinidazole ($296.0K). Total export value is $7.3M.

What is V S International Private Limited's total pharmaceutical export value?

V S International Private Limited's total pharmaceutical export value is $7.3M, based on 196 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does V S International Private Limited cover?

V S International Private Limited exports across 5 therapeutic categories. The largest are Antibiotics (51.5%, 1 products), Antivirals (36.1%, 2 products), Nutritional Supplements (7.2%, 1 products).

Get Full V S International Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.

V S International Private Limited

V S International Private Limited — Export Portfolio & Destination Treemap

Who is V S International Private Limited? — Company Overview & Market Position

What Does V S International Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

V S International Private Limited Therapeutic Categories — 5 Specializations